Clinical trial
A Randomized Phase II Trial to Assess the Predictive Value of Increased EGFR Copy Number by FISH in Patients With Advanced / Metastatic NSCLC Treated With Cetuximab and Carboplatin / Paclitaxel
NCT00768131 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Trial to Assess the Predictive Value of Increased EGFR Copy Number by FISH in Patients With Advanced / Metastatic NSCLC Treated With Cetuximab and Carboplatin / Paclitaxel
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- October 31, 2008
- Completion date
- October 31, 2008
- Enrollment
- 0 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.